Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze PTCT PTC Therapeutics, Inc.. Please read: https://finlab.finance/en/setup?stock=PTCT

No install, open FinLab Studio

PTCT

PTC Therapeutics, Inc. Healthcare As of 2026-07-31 Updated daily after market close

quality needs a look, discounted valuation.

1 active signal
EPS surprise beat
This page refreshes daily after the close. Add PTC Therapeutics, Inc. to your watchlist to track signal changes on your next visit.
Valuation 73Quality 47Growth 11Momentum 68Risk / liquidity 65

Is PTC Therapeutics, Inc. a buy? Fundamentals and valuation first

  • Quality is weaker than peers. Operating margin is only around the 26th percentile. TTM ROE is about 103.5%.

  • Valuation is cheaper than most peers. TTM P/E is in the 9th percentile, lower than most liquid US common stocks.

  • Recent volatility is moderate. 60-day annualized volatility is near the 58th percentile. Average 20-day dollar volume is about $117.8M.

  • Signals are active now. EPS surprise beat currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

EPS surprise beat

Active · now 289.3355903512484%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

18 historical occurrences (since 2015-05-04)
Average forward return after EPS surprise beat。20-day: Win 93.3%, Sample 15, Median +11.87%, Excess +17.22%, Beat mkt rate 100%；60-day: Win 78.6%, Sample 14, Median +13.24%, Excess +20.7%, Beat mkt rate 71.4%；120-day: Win 64.3%, Sample 14, Median +28.89%, Excess +32.74%, Beat mkt rate 71.4%

120 days after: historical avg +40.26%

20-day +18.77%
60-day +24.34%
120-day +40.26%
20-day
60-day
120-day
Win
93.3%
78.6%
64.3%
Sample
15
14
14
Median
+11.87%
+13.24%
+28.89%
Excess
+17.22%
+20.7%
+32.74%
Beat mkt rate
100%
71.4%
71.4%

Over 14 occurrences, 120-day forward avg gained 40.26%, beat the market by 32.74 pts; win rate 64.3%.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

19 times historically; 60-day forward avg +1.26%, win rate 44.4%, beating the market by +0.71 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

31 times historically; 60-day forward avg +13.79%, win rate 77.4%, beating the market by +11.39 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

17 times historically; 60-day forward avg +6.18%, win rate 58.8%, beating the market by +0.55 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.